Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) EBITDA (2016 - 2025)

Vanda Pharmaceuticals' EBITDA history spans 16 years, with the latest figure at -$40.0 million for Q4 2025.

  • On a quarterly basis, EBITDA fell 298.18% to -$40.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$150.1 million, a 277.04% decrease, with the full-year FY2025 number at -$150.1 million, down 277.04% from a year prior.
  • EBITDA hit -$40.0 million in Q4 2025 for Vanda Pharmaceuticals, down from -$31.0 million in the prior quarter.
  • Over the last five years, EBITDA for VNDA hit a ceiling of $12.7 million in Q2 2021 and a floor of -$40.8 million in Q1 2025.
  • Historically, EBITDA has averaged -$7.6 million across 5 years, with a median of -$6.3 million in 2023.
  • Biggest five-year swings in EBITDA: soared 4628.32% in 2021 and later crashed 493.42% in 2024.
  • Tracing VNDA's EBITDA over 5 years: stood at $9.0 million in 2021, then dropped by 22.96% to $6.9 million in 2022, then plummeted by 199.65% to -$6.9 million in 2023, then crashed by 46.0% to -$10.1 million in 2024, then crashed by 298.18% to -$40.0 million in 2025.
  • Business Quant data shows EBITDA for VNDA at -$40.0 million in Q4 2025, -$31.0 million in Q3 2025, and -$38.2 million in Q2 2025.